Itcure, a gene editing specialist based in Suzhou, has entered into a partnership with compatriot firm OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a gene and cell therapy Contract Research Organization (CRO). The collaboration aims to jointly explore and advance gene editing systems, gene editing fusion proteins (Cas12 protein), and non-integrated viral particle (VLP) delivery systems. This partnership seeks to promote the application of gene editing tools in fields such as immune cells, iPSC cells, and in vivo gene therapy.
Itcure’s Proprietary Technologies
Itcure is renowned for its world-leading proprietary enCas12Ultra gene editing/base editing/epigenetic toolkit and structurally unique VLP delivery system. These technologies enable efficient in vitro and in vivo target gene editing or long-acting target gene inhibition. Additionally, the system facilitates efficient and specific delivery of proteins, mRNA, or RNP protein complexes.-Fineline Info & Tech
